PROMETHAZINE, 5mg/5ml, oral solution, 100ml, bot
NST
DORAPROM5S1
Valid Article
HS Code:
300490
Last Updated on:
03/12/2024, 22:08:31
Former
Code(s):
DORAZTF0038 DORAZFR0579 DORAPROM038 DORAPROM5S2
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
R06AD02
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
PROMETHAZINE
- Not in the WHO list of Essential Medicines 2023 (removed in 2009) (Chlorpromazine as therapeutic equivalent)
Therapeutic Action
Sedative, antihistaminic, antiemetic
Indications
Agitation or aggressive behaviour in patients with acute or chronic psychosis, in association with haloperidol
Instructions for use
Precautions for Use
Administer with caution and monitor use:
- in elderly patients
- in patients with prostate disorders, closed-angle glaucoma, epilepsy, orthostatic hypotension, severe renal or hepatic impairment
- in case of concomitant use with CNS depressants (opioid analgesics, antipsychotics, sedatives, antidepressants, etc.) or other anticholinergic drugs (atropine, amitriptyline, chlorpromazine, etc.)
May cause:
- drowsiness, dizziness, headache, confusion, hypotension, photosensitivity
- anticholinergic effects (dry mouth, constipation, blurred vision, tachycardia, disorders of micturition)
- rarely: seizures, extrapyramidal syndrome, neuroleptic malignant syndrome (unexplained hyperthermia with neuromuscular disorders), allergic reactions
Contraindicated in patients with prolonged QT-interval or with risk factors for QT-interval prolongation.
Avoid in pregnancy and breast-feeding women.
Storage
Below 25°C - Protect from sunlight - Protect from humidity